Home > News > Industry > Pharma News > Sanofi India ropes in...

Sanofi India ropes in Himanshu Bakshi as General Manager for Consumer Healthcare business

By - Ruchika Sharma
Published On 2023-12-19 11:17 GMT   |   Update On 2023-12-21 05:41 GMT

Mumbai: Sanofi India Limited (SIL) today announced the appointment of Himanshu Bakshi as General Manager for its Consumer Healthcare (CHC) business, effective 15th January 2024.SIL earlier this year had announced that the Company’s Consumer Healthcare business will be demerged into its wholly owned subsidiary, Sanofi Consumer Healthcare India Limited (SCHIL), subject to necessary approvals...

Login or Register to read the full article
Register Now

Mumbai: Sanofi India Limited (SIL) today announced the appointment of Himanshu Bakshi as General Manager for its Consumer Healthcare (CHC) business, effective 15th January 2024.

SIL earlier this year had announced that the Company’s Consumer Healthcare business will be demerged into its wholly owned subsidiary, Sanofi Consumer Healthcare India Limited (SCHIL), subject to necessary approvals and sanction by the National Company Law Tribunal, Mumbai.

Himanshu has successfully led organizations in the business of FMCG (Fast Moving Consumer Goods) and healthcare products, through many transformation journeys -- from starting new businesses to scaling them up. In over two decades, Himanshu has worked in various roles across commercial, marketing, and general management in Indian and multinational companies.
He has led large and diverse teams by fostering a culture of growth and development in Reckitt Benckiser, PepsiCo and Dabur. His most recent stint was with Danone India as its Managing Director.
Himanshu will be a member of Sanofi India’s leadership team and senior management. He will also be a member of Sanofi’s AMEA (Africa, Middle East & Asia) Region leadership team, and CHC senior management.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

USFDA Advisory Committee to convene meeting to discuss on Eli Lilly Alzheimer's drug donanemab
Lupin net profit surges 52 percent at Rs 359 crore in Q4
Surprise check at pharmacies: Noida admin seizes samples of three medicines
Gland Pharma bags USFDA nod for amyotrophic lateral sclerosis injection Edaravone
AstraZeneca says it will withdraw COVID-19 vaccine globally
Biological E Gets CDSCO Panel Nod for Continued Safety study of 14-valent pneumococcal polysaccharide conjugate vaccine
Issue of pharma pricing control in Australia raised by India
Dialysis chain NephroPlus raises Rs 850 crores in Series F round from Quadria Capital